​

Halozyme Therapeutics (HALO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

HALO Stock Forecast

Halozyme Therapeutics (HALO) stock forecast, based on 22 Wall Street analysts, predicts a 12-month average price target of $52.00, with a high of $52.00 and a low of $52.00. This represents a -11.59% decline from the last price of $58.82.

$35 $41 $47 $53 $59 $65 High: $52 Avg: $52 Low: $52 Last Closed Price: $58.82

HALO Stock Rating

Halozyme Therapeutics stock's rating consensus is Buy, based on 22 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 16 Buy (72.73%), 6 Hold (27.27%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 22 0 6 16 Strong Sell Sell Hold Buy Strong Buy

HALO Price Target Upside V Benchmarks

TypeNameUpside
StockHalozyme Therapeutics-11.59%
SectorHealthcare Stocks 33.91%
IndustryBiotech Stocks 83.49%

Price Target Trends

1M3M12M
# Anlaysts--5
Avg Price Target--$54.00
Last Closing Price$58.82$58.82$58.82
Upside/Downside---8.19%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25333--9
Mar, 25334--10
Feb, 25234--9
Jan, 25234--9
Dec, 24235--10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 15, 2024Joseph CatanzaroPiper Sandler$52.00$46.7211.30%-11.59%
Jun 07, 2024Mitchell KapoorH.C. Wainwright$65.00$51.4426.36%10.51%
Jun 07, 2024Joseph CatanzaroPiper Sandler$51.00$51.44-0.86%-13.29%
Jun 07, 2024Mohit BansalWells Fargo$58.00$51.4412.75%-1.39%
Jun 06, 2024Corinne JenkinsGoldman Sachs$44.00$51.44-14.46%-25.20%
Jan 11, 2023Leerink Partners$61.00$55.709.52%3.71%
Dec 21, 2022Morgan Stanley$65.00$58.6310.86%10.51%
Nov 28, 2022Wells Fargo$65.00$55.5417.03%10.51%
Nov 22, 2022J.P. Morgan$54.00$52.742.39%-8.19%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 10, 2025H.C. WainwrightBuyBuyhold
Nov 15, 2024Piper SandlerNeutralNeutralhold
Nov 04, 2024Piper SandlerNeutralNeutralhold
Nov 01, 2024Leerink PartnersMarket PerformMarket Performhold
Oct 18, 2024Cowen & Co.BuyBuyhold
Oct 07, 2024Wells FargoMarket OutperformEqual-Weightdowngrade
Oct 04, 2024H.C. WainwrightBuyBuyhold
Sep 13, 2024Goldman SachsUnderperformUnderperformhold
Sep 13, 2024H.C. WainwrightBuyBuyhold
Aug 07, 2024Cowen & Co.BuyBuyhold

Financial Forecast

EPS Forecast

$0 $2 $4 $6 $8 $10 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.95$2.86$1.48$2.13$3.50----
Avg Forecast$0.93$2.68$1.32$2.77$4.13$5.05$6.92$8.33$8.84
High Forecast$0.95$2.76$1.41$2.79$4.19$5.35$7.86$8.54$9.06
Low Forecast$0.90$2.62$1.28$2.74$4.08$4.72$6.24$7.90$8.63
Surprise %2.15%6.72%12.12%-23.10%-15.25%----

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$267.59M$443.31M$660.12M$829.25M$1.02B----
Avg Forecast$265.21M$443.24M$671.79M$830.53M$1.00B$1.19B$1.47B$1.71B$1.83B
High Forecast$271.33M$453.46M$708.75M$838.20M$1.02B$1.21B$1.47B$1.72B$1.87B
Low Forecast$260.11M$434.71M$658.04M$827.36M$990.77M$1.18B$1.46B$1.71B$1.80B
Surprise %0.90%0.02%-1.74%-0.15%1.18%----

Net Income Forecast

$0 $300M $600M $900M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$129.09M$402.71M$202.13M$281.59M$444.09M----
Avg Forecast$129.76M$279.99M$331.72M$281.59M$554.68M$675.23M$946.10M$1.10B$1.19B
High Forecast$158.40M$335.99M$398.06M$337.91M$562.06M$717.60M$1.05B$1.15B$1.22B
Low Forecast$101.12M$224.00M$265.38M$225.28M$547.30M$632.86M$837.53M$1.06B$1.16B
Surprise %-0.52%43.83%-39.07%--19.94%----

HALO Forecast FAQ

Is Halozyme Therapeutics stock a buy?

Halozyme Therapeutics stock has a consensus rating of Buy, based on 22 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 16 Buy, 6 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Halozyme Therapeutics is a favorable investment for most analysts.

What is Halozyme Therapeutics's price target?

Halozyme Therapeutics's price target, set by 22 Wall Street analysts, averages $52 over the next 12 months. The price target range spans from $52 at the low end to $52 at the high end, suggesting a potential -11.59% change from the previous closing price of $58.82.

How does Halozyme Therapeutics stock forecast compare to its benchmarks?

Halozyme Therapeutics's stock forecast shows a -11.59% downside, underperforming the average forecast for the healthcare stocks sector (33.91%) and underperforming the biotech stocks industry (83.49%).

What is the breakdown of analyst ratings for Halozyme Therapeutics over the past three months?

  • April 2025: 33.33% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 30.00% Strong Buy, 30.00% Buy, 40.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 22.22% Strong Buy, 33.33% Buy, 44.44% Hold, 0% Sell, 0% Strong Sell.

What is Halozyme Therapeutics’s EPS forecast?

Halozyme Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $5.05, marking a 44.29% increase from the reported $3.5 in 2024. Estimates for the following years are $6.92 in 2026, $8.33 in 2027, and $8.84 in 2028.

What is Halozyme Therapeutics’s revenue forecast?

Halozyme Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $1.19B, reflecting a 16.87% increase from the reported $1.02B in 2024. The forecast for 2026 is $1.47B, followed by $1.71B for 2027, and $1.83B for 2028.

What is Halozyme Therapeutics’s net income forecast?

Halozyme Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $675.23M, representing an 52.05% increase from the reported $444.09M in 2024. Projections indicate $946.1M in 2026, $1.1B in 2027, and $1.19B in 2028.